Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer

CT Clinical Trial

Official title:

Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04977596
• Other study ID #: yurisheng
• Status: Completed
• Start date: January 1, 2012
• Est. completion date: June 25, 2019

Study information

• Verified date: March 2020
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied;

2. The CT imaging findings of G3 stage PNET and pancreatic cancer were compared to establish a Logistic regression diagnostic model, and the survival analysis of the two was compared.

3. Cox regression was used to study the risk factors for survival prognosis of well-differentiated and poorly differentiated PNET based on CT image features

Description:

According to the latest WHO Classification of Neuroendocrine Neoplasms (NET) in 2019, pancreatic neuroendocrine neoplasms (PNET) are divided into well-differentiated and poorly differentiated PNETs.The former is divided into G1, G2, and well differentiated G3.There are few studies on the survival outcomes of these two differentiated PNET types.The G3 imaging manifestations of the two types of differentiation have not been studied yet, and G3 PNET is often clinically misdiagnosed as pancreatic cancer, so it is necessary to differentiate the imaging manifestations and survival time of the two types.

A total of 71 patients with PNET in our hospital from January 2012 to January 2019 and 58 patients with pancreatic cancer from February 2014 to August 2015 were retrospectively collected. Complete survival time data of all patients after telephone follow-up were obtained.Since G3 PNET is very rare, the investigators enrolled 9 patients with G3 PNET in the First Affiliated Hospital of Zhejiang University School of Medicine and 7 patients with G3 PNET in the Affiliated Hospital of Air Force Military Medical University from January 2013 to October 2018.

CT images of PNET and pancreatic cancer were analyzed independently by two radiologists specializing in abdominal diagnosis, in which G3 lesions were evaluated simultaneously on MRI images and the others were evaluated only on CT images.Records clinical data and imaging characteristics: gender, age, tumor markers, tumor shape, size, tumor characteristics, edge, the expansion of the shrinking, pancreas, pancreatic pancreatitis, enhancement scan, arterial phase and portal phase lesions and the ratio of pancreatic parenchyma around, liver metastasis, peripheral vascular invasion, lymph node metastasis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: June 25, 2019
• Est. primary completion date: January 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Diagnosis by pathology and detailed pathological information

2. Enhanced CT examination or biopsy were performed within 2 months before surgery

3. There was no preoperative radiotherapy or chemotherapy

Exclusion Criteria:

1. No Ki-67 index

2. CT value cannot be measured by ROI because of pancreatic atrophy and other reasons

3. No enhanced images or missing images

Related Conditions & MeSH terms

• Carcinoma, Pancreatic
• CT
• Neuroendocrine Tumors
• Pancreatic Neoplasms

Intervention

Other:
• No intervention
Retrospective study without intervention

Locations

Country	Name	City	State
China	Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang

Sponsors (3)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University	The First Affiliated Hospital of the Fourth Military Medical University, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor size	Maximum surface size of the lesion (cm)	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Tumor location	Locations of the pancreas: head, neck, body and tail	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Number of lesions	Number of lesions	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Margin	well-defined or ill-defined	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	tumor texture	solid;solid and cystic;complex cystic	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Pancreatic tail contraction	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Complicated pancreatitis	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Pancreatic duct/bile duct dilatation	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Extrapancreatic tissue invasion	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Hepatic metastasis	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	Lymphatic metastasis	yes or no	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of pancreas plain scan	CT value of pancreas plain scan	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of lesion plain scan	CT value of lesion plain scan	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of pancreas artery phase	CT value of pancreas artery phase	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of lesion artery phase	CT value of lesion artery phase	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of pancreas portal phase	CT value of pancreas portal phase	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy
Primary	CT value of lesion portal phase	CT value of lesion portal phase	preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy